• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

    2/2/24 12:00:00 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYBX alert in real time by email

    Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study

    SYNB1353 was well-tolerated, with similar proportions in both the placebo and active arms reporting mild-moderate gastrointestinal adverse events

    CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clinical proof of mechanism in healthy volunteers through the successful lowering of methionine (Met), a precursor to homocysteine, in a dietary model of classical homocystinuria (HCU).

    Among findings outlined in the manuscript, SYNB1353 efficiently degraded both dietary and entero-recirculating methionine to prevent its absorption and subsequent conversion to homocysteine in preclinical models, suggesting that SYNB1353 should result in lowering of plasma homocysteine levels in HCU patients. In addition, in results from the clinical study in healthy volunteers, SYNB1353 was generally well-tolerated and adverse events were mild to moderate, transient, and predominantly gastrointestinal in nature. The proportion of subjects reporting gastrointestinal events were similar for the SYNB1353 and placebo cohorts (36.4% and 37.5%, respectively).

    "Given the significant disease burden and acute need for new treatment options for those affected by classical HCU, we are pleased to share these findings that highlight the potential of our novel approach, which targets methionine, an amino acid that has long been validated as a therapeutic target in classical HCU through the use of dietary restrictions," said Mylène Perreault, Ph.D., Head of Research at Synlogic. "Importantly, the SYNB1353 program has built on learnings and progress from our other rare metabolic disease programs, including the design of the potential therapeutic, the preclinical research and the advancement in clinical development."

    The publication, entitled "The Live Biotherapeutic SYNB1353 Decreases Plasma Methionine via Directed Degradation in Animal Models and Healthy Volunteers," and published in the peer-reviewed journal, Cell Host & Microbe, is now available online at https://www.sciencedirect.com/science/article/pii/S193131282400009X.  

    About Classical Homocystinuria (HCU) & SYNB1353

    Classical homocystinuria (HCU) is a rare metabolic disease characterized by extreme levels of homocysteine caused by an inherited deficiency in the cystathionine beta-synthase (CBS) enzyme. When CBS is absent, homocysteine builds up, putting patients at risk of multisystem complications, including potentially life-threatening, acute thromboembolic events, optical damage from lens dislocation, skeletal deficiencies, and neurocognitive impairments. Methionine (Met), an essential amino acid in dietary protein, is a precursor to homocysteine, and a restrictive, low-Met diet is a standard treatment for lowering total homocysteine (tHcy). SYNB1353 is a novel, orally administered, non-systemically absorbed drug candidate designed to consume Met in the gastrointestinal tract, thereby lowering homocysteine levels in patients with HCU. It is the first drug candidate developed through a research collaboration between Synlogic and Ginkgo Bioworks and the first investigational medicine developed on Ginkgo's platform to enter the clinic. The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation, Fast Track designation and Orphan Drug Designation (ODD) to SYNB1353 for the potential treatment of HCU. Synlogic holds worldwide development and commercialization rights to SYNB1353.

    About Synlogic

    Synlogic is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases in need of new treatment options. The Company focuses on rare metabolic diseases, with its lead program, labafenogene marselecobac (SYNB1934), currently being studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for classical homocystinuria (HCU). Both PKU and HCU are caused by inborn errors of metabolism, and present significant need for innovation due to limitations of today's medical treatment options.

    Synlogic's early-stage pipeline includes research and development on product candidates addressing medical needs in enteric hyperoxaluria, gout, cystinuria, as well as inflammatory bowel disease (IBD). The Company's productivity is fueled by a reproducible, proprietary approach that creates new enzymatic pathways designed to consume or produce specific biological targets provided in GI-restricted, orally administered biopharmaceuticals. Synlogic designs, develops and manufactures these drug candidates, which are produced by applying precision genetic engineering to well-characterized probiotics. For more information, please visit www.synlogictx.com or follow us on Twitter, LinkedIn, Facebook, Instagram, and YouTube.

    Forward Looking Statements

    This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "look forward, " "estimate," "expect," "focused on," "intend," "on track, " "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of labafenogene marselecobac (previously known as SYNB1934), SYNB1353, SYNB8802 and SYNB2081 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

    Media Contact: [email protected]

    Investor Relations: [email protected] 



    Primary Logo

    Get the next $SYBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYBX

    DatePrice TargetRatingAnalyst
    11/24/2021$7.00Perform → Outperform
    Oppenheimer
    11/24/2021Perform → Outperform
    Oppenheimer
    11/11/2021$15.00 → $11.00Outperform
    SVB Leerink
    10/13/2021$9.00 → $7.00Buy
    HC Wainwright & Co.
    9/20/2021$7.00 → $9.00Overweight
    Piper Sandler
    6/28/2021$13.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SYBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Synlogic Reports Third Quarter 2024 Financial Results

      WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update. As previously announced, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Synlogic Board of Di

      11/12/24 4:35:09 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports Second Quarter 2024 Financial Results

      WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetab

      8/8/24 7:00:52 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports First Quarter 2024 Financial Results

      CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetable fo

      5/14/24 7:00:28 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Synlogic upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Synlogic from Perform to Outperform and set a new price target of $7.00

      11/24/21 7:28:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic upgraded by Oppenheimer

      Oppenheimer upgraded Synlogic from Perform to Outperform

      11/24/21 4:55:59 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Synlogic with a new price target

      SVB Leerink reiterated coverage of Synlogic with a rating of Outperform and set a new price target of $11.00 from $15.00 previously

      11/11/21 5:14:48 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

      – Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU) – - Platform presentation and two poster presentations at SIMD Annual Meeting – – $77.6 million in cash, cash equivalents and marketable securities support projected runway into second half of 2024 –    CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. "

      3/29/23 6:40:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

      CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Dr. Dave Hava to Head of Research and Development effective January 1, 2023. "Developing a new therapeutic modality requires seamless integration of research and clinical development so that learnings from the clinic can be immediately applied to earlier programs," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "Since joining the company, Dave has demonstrated the attributes required

      1/3/23 6:58:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

      SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      11/14/24 4:40:57 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Synlogic Inc. (Amendment)

      SC 13D/A - SYNLOGIC, INC. (0001527599) (Subject)

      5/16/24 7:44:32 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Synlogic Inc.

      SC 13G - SYNLOGIC, INC. (0001527599) (Subject)

      4/18/24 11:18:42 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Synlogic Inc.

      10-Q - SYNLOGIC, INC. (0001527599) (Filer)

      5/8/25 4:30:30 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Synlogic Inc.

      10-K/A - SYNLOGIC, INC. (0001527599) (Filer)

      4/30/25 11:57:58 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Synlogic Inc.

      10-K - SYNLOGIC, INC. (0001527599) (Filer)

      3/6/25 4:47:33 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Financials

    Live finance-specific insights

    See more
    • Synlogic Adopts Limited Duration Stockholders Rights Plan

      CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the "Board") has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right") for each outstanding share of common stock. The dividend distribution will be made on March 1, 2024, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025. The Company also

      2/20/24 12:15:26 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

      Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar across placebo and active arms Synlogic to host webcast today at 8:30 am. ET with Dr. Kyle Wood, Associate Professor, Urology,​ University of Alabama ​at Birmingham  CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB8802 has demonstrated proof of concept through clinically significant

      12/15/22 6:59:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

      Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of activity across all assessed endpoints Company confirms SYNB1934 as candidate for Phase 3 initiation expected in H1 2023 Synlogic to Host Webcast Today at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced positive top-line data from the Phase 2 Synpheny-1 study in phenylketonuri

      10/18/22 6:59:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shea Richard P was granted 15,000 shares, increasing direct ownership by 2,964% to 15,506 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:46:11 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Flynn James P was granted 15,000 shares (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:43:44 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Dooley Mary Beth sold $173 worth of shares (144 units at $1.20), decreasing direct ownership by 1% to 12,901 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/3/25 4:30:42 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care